No Data
No Data
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2024
Analysts Have Conflicting Sentiments on These Healthcare Companies: Unicycive Therapeutics (UNCY), LifeMD (LFMD) and Teladoc (TDOC)
KeyBanc Maintains LifeMD(LFMD.US) With Buy Rating, Cuts Target Price to $10
KeyBanc analyst Scott Schoenhaus maintains $LifeMD(LFMD.US)$ with a buy rating, and adjusts the target price from $12 to $10.According to TipRanks data, the analyst has a success rate of 31.9% and a
LifeMD Is Maintained at Overweight by Keybanc
LifeMD Is Maintained at Overweight by
LifeMD Price Target Cut to $10.00/Share From $12.00 by Keybanc
LifeMD Price Target Cut to $10.00/Share From $12.00 by
Express News | Keybanc Maintains Overweight on LifeMD, Lowers Price Target to $10